Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant α1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial-Reference-Cited by-同舟云学术

Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant α1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial

Published:2012-04 Issue:4 Volume:79 Page:875-882
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Goldfischer Evan,Kowalczyk John J.,Clark William R.,Brady Erin,Shane Michael Anne,Dgetluck Nancy,Klise Suzanne R.

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. Update on AUA guideline on the management of benign prostatic hyperplasia;McVary;J Urol,2011

2. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia;McVary;J Urol,2007

3. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study;Roehrborn;J Urol,2008

4. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial;McVary;J Urol,2007

5. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia;Stief;Eur Urol,2008

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Outpatient Therapies and Treatment of Benign Prostatic Hyperplasia;Medical Clinics of North America;2024-09

2. Medical Advancements in Benign Prostatic Hyperplasia Treatments;Current Urology Reports;2024-03-07

3. Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts;Frontiers in Pharmacology;2023-10-09

4. Persistence to Medications for Benign Prostatic Hyperplasia/Benign Prostatic Obstruction-Associated Lower Urinary Tract Symptoms in the ASL TO4 Regione Piemonte (Italy);Healthcare;2022-12-17

5. Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis;International Journal of Clinical Practice;2022-11-03